Patient-facing guidance from MedlinePlus emphasizes coordinating dose changes with your clinician to avoid uncontrolled glucose and adverse effects, not self-adjusting on your own
Reported issues, usually mild, include redness, itching, or contact sensitivity, particularly when GHK-Cu is combined with strong actives like retinoids or exfoliating acids
One standout mechanism involves managing inflammation by guiding immune cells, specifically macrophages, from a pro-inflammatory state (M1 phenotype) to a pro-repair state (M2 phenotype)
The safety profile of combined therapy remains excellent, with no unexpected drug interactions reported in clinical trials or real-world practice
IV therapy allows NAD to enter the bloodstream directly over time, supporting higher total dosing and more controlled delivery